^
Association details:
Biomarker:No biomarker
Cancer:Peritoneal Cancer
Drug:Mvasi (bevacizumab-awwb) (VEGF-A inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Excerpt:
Mvasi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer...Mvasi in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer...
Secondary therapy:
pegylated liposomal doxorubicin; carboplatin + paclitaxel; carboplatin + gemcitabine; topotecan